Brody H. Placebo effect: an examination of Grunbaum's definition. In: White L, Tursky B, Schwartz GE, eds. Placebo: theory, research, and mechanisms. New York: Guilford Press, 1985; 37–58.
Turner JA, Deyo RA, Loeser JD, et al. The importance of placebo effects in pain treatment and research. JAMA 1994; 271: 1609–1614.
US FDA. Freedom of Information summary. Rimadyl (carprofen) caplets for dogs. S/NADA 141-053. Available at: www.fda.gov/downloads/…/FOIADrugSummaries/ucm116543.pdf. Accessed Jul 8, 2009.
US FDA. Freedom of Information summary. Deramaxx chewable tablets (deracoxib). Supplemental NADA 141-203. Available at: www.fda.gov/downloads/…/FOIADrugSummaries/ucm117645.pdf. Accessed Jul 8, 2009.
Peterson KD, Keefe TJ. Effects of meloxicam on severity of lameness and other clinical signs of osteoarthritis in dogs. J Am Vet Med Assoc 2004; 225: 1056–1060.
Hercock CA, Pinchbeck G, Giejda A, et al. Validation of a client-based clinical metrology instrument for the evaluation of canine elbow osteoarthritis. J Small Anim Pract 2009; 50: 266–271.
Moreau M, Lussier B, Doucet M, et al. Efficacy of licofelone in dogs with clinical osteoarthritis. Vet Rec 2007; 160: 584–588.
Innes JF, Fuller CJ, Grover ER, et al. Randomised, double-blind, placebo-controlled parallel group study of P54FP for the treatment of dogs with osteoarthritis. Vet Rec 2003; 152: 457–460.
Moreau M, Dupuis J, Bonneau NH, et al. Clinical evaluation of a powder of quality elk velvet antler for the treatment of osteoarthrosis in dogs. Can Vet J 2004; 45: 133–139.
Vasseur PB, Johnson AL, Budsberg SC, et al. Randomized, controlled trial of the efficacy of carprofen, a nonsteroidal antiinflammatory drug, in the treatment of osteoarthritis in dogs. J Am Vet Med Assoc 1995; 206: 807–811.
Brown DC, Boston RC, Coyne JC, et al. Ability of the canine brief pain inventory to detect response to treatment in dogs with osteoarthritis. J Am Vet Med Assoc 2008; 233: 1278–1283.
Roush JK, Cross AR, Renberg WC, et al. Evaluation of the effects of dietary supplementation with fish oil omega-3 fatty acids on weight bearing in dogs with osteoarthritis. J Am Vet Med Assoc 2010; 236: 67–73.
Brown WA. Understanding and using the placebo effect. Psychiatric Times 2006; 23: 15–17.
Waschbusch DA, Pelham WE, Waxmonsky J, et al. Are there placebo effects in the medication treatment of children with attention-deficit hyperactivity disorder? J Dev Behav Pediatr 2009; 30: 158–168.
Waxman AW, Robinson DA, Evans R, et al. Relationship between objective and subjective assessment of limb function in normal dogs with an experimentally induced lameness. Vet Surg 2008; 37: 241–246.
Brown DC, Boston RC, Farrar JT. Use of an activity monitor to detect response to treatment in dogs with osteoarthritis. J Am Vet Med Assoc 2010; 237: 66–70.
Budsberg SC, Johnston SA, Schwarz PD, et al. Efficacy of etodolac for the treatment of osteoarthritis of the hip joints in dogs. J Am Vet Med Assoc 1999; 214: 206–210.
Burton NJ, Owen MR, Colborne GR, et al. Can owners and clinicians assess outcome in dogs with fragmented medial coronoid process? Vet Comp Orthop Traumatol 2009; 22: 183–189.
Everitt BS. Response feature analysis of longitudinal data. In: Everitt BS, Pickles A, eds. Statistical aspects of the design and analysis of clinical trials. River Edge, NY: World Scientific Publishing, 2004; 119–132.
Advertisement
Objective—To document the caregiver placebo effect in owners and veterinarians of dogs with lameness from osteoarthritis.
Design—Prospective, randomized, double-blinded, placebo-controlled, multicenter clinical trial.
Animals—58 dogs with lameness secondary to osteoarthritis.
Procedures—Dogs enrolled in the placebo arm of an FDA-approved study were evaluated to determine the relationship between subjective (caregiver responses) and objective (force platform gait analysis) patient outcome measures.
Results—A caregiver placebo effect for owners evaluating their dog's lameness occurred 39.7% of the time. A caregiver placebo effect occurred 44.8% of the time when veterinarians examined dogs for lameness at a walk, 44.8% of the time when veterinarians examined dogs for lameness at a trot, and 43.1% of the time when veterinarians evaluated dogs for signs of pain on palpation of the joint. This effect was significantly enhanced with time. Mean ground reaction forces (GRFs) remained unchanged for dogs during treatment with the placebo. Individually, of 58 dogs, 5 had GRFs that worsened by ≥ 5% over 42 days, 7 had GRFs that improved by ≥ 5% over 42 days, and 46 had GRFs that remained unchanged.
Conclusions and Clinical Relevance—A caregiver placebo effect was common in the evaluation of patient response to treatment for osteoarthritis by both pet owners and veterinarians. Force platform gait analysis was an unbiased outcome measure for dogs with lameness from osteoarthritis. A caregiver placebo effect should be considered when interpreting owner and veterinary reports of patient response to treatment.
Novartis Animal Health provided access to the raw data used for this study.